An international research agenda for clozapine-resistant schizophrenia

氯氮平 精神分裂症(面向对象编程) 精神科 生活质量(医疗保健) 医学 临床试验 心理学 心理治疗师 病理
作者
Jurjen J. Luykx,Jairo M. González-Díaz,Ta‐Wei Guu,Marte Z. van der Horst,Edwin van Dellen,Marco P. Boks,Sinan Gülöksüz,Lynn E. DeLisi,Iris E. Sommer,Russel Cummins,David Shiers,Jimmy Lee,Susanna Every‐Palmer,Ahmed Mhalla,Zohra Chadly,Sherry Kit Wa Chan,Robert O. Cotes,Shun Takahashi,Michael E. Benros,Elias Wagner
出处
期刊:The Lancet Psychiatry [Elsevier]
卷期号:10 (8): 644-652 被引量:14
标识
DOI:10.1016/s2215-0366(23)00109-8
摘要

Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
estrella完成签到 ,获得积分10
1秒前
FYm完成签到,获得积分10
1秒前
2秒前
2秒前
WJing发布了新的文献求助10
3秒前
量子星尘发布了新的文献求助10
3秒前
4秒前
butterfly完成签到,获得积分10
5秒前
丹青完成签到 ,获得积分10
5秒前
5秒前
老魏完成签到,获得积分10
6秒前
大个应助Ther采纳,获得10
6秒前
天才小能喵完成签到 ,获得积分0
6秒前
HuanChen完成签到,获得积分10
7秒前
苗广山完成签到,获得积分10
7秒前
stop here完成签到,获得积分10
7秒前
8秒前
hhh发布了新的文献求助10
8秒前
10秒前
semiaa完成签到,获得积分10
10秒前
汉堡包应助小猪采纳,获得10
13秒前
甜蜜的荟发布了新的文献求助10
13秒前
芜6完成签到,获得积分10
15秒前
berkelerey12138完成签到,获得积分10
15秒前
刘雪完成签到 ,获得积分10
16秒前
完美梨愁完成签到 ,获得积分10
16秒前
yyy完成签到,获得积分10
16秒前
李健的粉丝团团长应助zzzz采纳,获得10
17秒前
Dudidu完成签到,获得积分10
17秒前
一颗大树完成签到,获得积分10
18秒前
潇洒的浩然完成签到,获得积分10
19秒前
比比谁的速度快应助曾珍采纳,获得50
19秒前
21秒前
NiNi完成签到,获得积分10
22秒前
Ther完成签到,获得积分20
23秒前
傲娇白安完成签到,获得积分10
24秒前
24秒前
甜蜜的荟完成签到,获得积分20
25秒前
婷儿完成签到,获得积分10
25秒前
牛牛发布了新的文献求助10
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029